RT Journal Article
SR Electronic
T1 Understanding monogenic Parkinson’s disease at a global scale
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.12.24304154
DO 10.1101/2024.03.12.24304154
A1 Junker, Johanna
A1 Lange, Lara M.
A1 Vollstedt, Eva-Juliane
A1 Roopnarain, Karisha
A1 Doquenia, Maria Leila M.
A1 Annuar, Azlina Ahmad
A1 Avenali, Micol
A1 Bardien, Soraya
A1 Bahr, Natascha
A1 Ellis, Melina
A1 Galandra, Caterina
A1 Gasser, Thomas
A1 Heutink, Peter
A1 Illarionova, Anastasia
A1 Kanana, Yuliia
A1 Sarmiento, Ignacio J. Keller
A1 Kumar, Kishore R.
A1 Lim, Shen-Yang
A1 Madoev, Harutyun
A1 Mata, Ignacio F.
A1 Mencacci, Niccolò E.
A1 Nalls, Mike A.
A1 Padmanabhan, Shalini
A1 Shambetova, Cholpon
A1 Solle, J
A1 Tan, Ai-Huey
A1 Trinh, Joanne
A1 Valente, Enza Maria
A1 Singleton, Andrew
A1 Blauwendraat, Cornelis
A1 Lohmann, Katja
A1 Fang, Zih-Hua
A1 Klein, Christine
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/04/09/2024.03.12.24304154.abstract
AB Until recently, about three-quarters of all monogenic Parkinson’s disease (PD) studies were performed in European/White ancestry, thereby severely limiting our insights into genotype-phenotype relationships at global scale. The first systematic approach to embrace monogenic PD worldwide, The Michael J. Fox Foundation Global Monogenic PD (MJFF GMPD) Project, contacted authors of publications reporting individuals carrying pathogenic variants in known PD-causing genes. In contrast, the Global Parkinson’s Genetics Program’s (GP2) Monogenic Network took a different approach by targeting PD centers not yet represented in the medical literature. Here, we describe combining both efforts in a “merger project” resulting in a global monogenic PD cohort with build-up of a sustainable infrastructure to identify the multi-ancestry spectrum of monogenic PD and enable studies of factors modifying penetrance and expression of monogenic PD. This effort demonstrates the value of future research based on team science approaches to generate comprehensive and globally relevant results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project number ZO1 AG000534, as well as the National Institute of Neurological Disorders and Stroke. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (https://gp2.org). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:There is no overall GP2 Ethics approval. All institutions participating in GP2 have obtained approval from their local Ethics committees which is a prerequisite to be part of the GP2 project. All Ethics approvals and patient information sheets and consent forms were reviewed by GP2's Compliance working group in order to ensure that sample and data sharing is allowed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized data are available upon reasonable request from any qualified investigator to the authors.